Jean Davignon

Summary

Affiliation: Clinical Research Institute of Montreal
Country: Canada

Publications

  1. pmc Pleiotropic effects of pitavastatin
    Jean Davignon
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montréal IRCM and University of Montréal, QC, Canada
    Br J Clin Pharmacol 73:518-35. 2012
  2. pmc Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels
    Jean Davignon
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, QC H2W1R7, Canada
    Trans Am Clin Climatol Assoc 120:163-73. 2009
  3. doi request reprint The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis
    Jean Davignon
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal IRCM, 110 Pine Avenue West, Montreal, QC, H2W 1R7, Canada
    Curr Atheroscler Rep 12:308-15. 2010
  4. doi request reprint Characterization of a new LCAT mutation causing familial LCAT deficiency (FLD) and the role of APOE as a modifier gene of the FLD phenotype
    Alexis Baass
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal IRCM, Montreal, QC, Canada
    Atherosclerosis 207:452-7. 2009
  5. doi request reprint High expression of apolipoprotein E impairs lipid storage and promotes cell proliferation in human adipocytes
    Jean François Carmel
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Montreal, Quebec, Canada
    J Cell Biochem 106:608-17. 2009
  6. pmc Ongoing clinical trials of the pleiotropic effects of statins
    Jean Davignon
    Clinical Research Institute of Montreal, Montreal, QC, Canada
    Vasc Health Risk Manag 1:29-40. 2005
  7. ncbi request reprint Synthesis and secretion of apoC-I and apoE during maturation of human SW872 liposarcoma cells
    Hanny Wassef
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Montreal, Quebec, Canada
    J Nutr 134:2935-41. 2004
  8. pmc A new method for measurement of total plasma PCSK9: clinical applications
    Geneviève Dubuc
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Montreal, Quebec, Canada
    J Lipid Res 51:140-9. 2010
  9. ncbi request reprint The antioxidant effects of statins
    Jean Davignon
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, and University of Montreal Hospital Medical Centre, Montreal, QC, Canada
    Coron Artery Dis 15:251-8. 2004
  10. ncbi request reprint Emphasis on pleiotropic effects, a new paradigm shift?
    Jean Davignon
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, and University of Montreal Hospital Medical Centre, Montreal, QC, Canada
    Coron Artery Dis 15:223-5. 2004

Collaborators

Detail Information

Publications12

  1. pmc Pleiotropic effects of pitavastatin
    Jean Davignon
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montréal IRCM and University of Montréal, QC, Canada
    Br J Clin Pharmacol 73:518-35. 2012
    ..It is concluded that the diverse pleiotropic actions of pitavastatin may contribute to reducing cardiovascular morbidity and mortality beyond that achieved through LDL-C reduction...
  2. pmc Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels
    Jean Davignon
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, QC H2W1R7, Canada
    Trans Am Clin Climatol Assoc 120:163-73. 2009
    ....
  3. doi request reprint The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis
    Jean Davignon
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal IRCM, 110 Pine Avenue West, Montreal, QC, H2W 1R7, Canada
    Curr Atheroscler Rep 12:308-15. 2010
    ..Which one will be clinically applicable will depend on long-term effects, cost, and ease of administration...
  4. doi request reprint Characterization of a new LCAT mutation causing familial LCAT deficiency (FLD) and the role of APOE as a modifier gene of the FLD phenotype
    Alexis Baass
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal IRCM, Montreal, QC, Canada
    Atherosclerosis 207:452-7. 2009
    ..Our results suggest that a LCAT-/- genotype associated with an APOE epsilon2 allele could be a novel mechanism leading to dysbetalipoproteinemia...
  5. doi request reprint High expression of apolipoprotein E impairs lipid storage and promotes cell proliferation in human adipocytes
    Jean François Carmel
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Montreal, Quebec, Canada
    J Cell Biochem 106:608-17. 2009
    ..These results bring new evidence of apoE-involvement in metabolic disorders at the adipocyte level...
  6. pmc Ongoing clinical trials of the pleiotropic effects of statins
    Jean Davignon
    Clinical Research Institute of Montreal, Montreal, QC, Canada
    Vasc Health Risk Manag 1:29-40. 2005
    ..The multiple effects (ie, pleiotropic effects of statins) have received increasing recognition and may have clinical applicability across a broad range of cardiovascular and noncardiovascular conditions...
  7. ncbi request reprint Synthesis and secretion of apoC-I and apoE during maturation of human SW872 liposarcoma cells
    Hanny Wassef
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Montreal, Quebec, Canada
    J Nutr 134:2935-41. 2004
    ..Furthermore, apoC-I and apoE production are differentially regulated at the transcriptional level, and long-term treatment with insulin has an inhibitory rather than stimulatory effect on apoC-I and apoE production...
  8. pmc A new method for measurement of total plasma PCSK9: clinical applications
    Geneviève Dubuc
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Montreal, Quebec, Canada
    J Lipid Res 51:140-9. 2010
    ..316, P < 0.02 in FH and r = 0.275, P < 0.009 in non-FH). The detection of circulating PCSK9 in both FH and non-FH subjects means that this assay could be used to monitor response to therapy in a wide range of patients...
  9. ncbi request reprint The antioxidant effects of statins
    Jean Davignon
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, and University of Montreal Hospital Medical Centre, Montreal, QC, Canada
    Coron Artery Dis 15:251-8. 2004
    ..The antioxidant properties of statins extend to organ protection especially the myocardium and the lungs...
  10. ncbi request reprint Emphasis on pleiotropic effects, a new paradigm shift?
    Jean Davignon
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, and University of Montreal Hospital Medical Centre, Montreal, QC, Canada
    Coron Artery Dis 15:223-5. 2004
  11. ncbi request reprint Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity
    Jeffrey S Cohn
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Quebec, Canada, H2W 1R7
    J Clin Endocrinol Metab 89:3949-55. 2004
    ....
  12. ncbi request reprint Beneficial cardiovascular pleiotropic effects of statins
    Jean Davignon
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Montreal, Quebec, Canada
    Circulation 109:III39-43. 2004
    ..Understanding the pleiotropic effects of statins is important to optimize their use in treatment and prevention of cardiovascular disease...